| NDC包装代码 | 产品NDC | 产品类型 | 商品名 | 通用名 | 剂型 | 给药途径 | 上市日期 | 结束日期 | 市场类别 | 申请号 | 标签持有者 | 活性成分 | 规格 | 包装描述 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 84612-855-01 | 84612-855 | HUMAN PRESCRIPTION DRUG | WEZLANA | ustekinumab-auub | INJECTION, SOLUTION | SUBCUTANEOUS | 20250101 | N/A | BLA | BLA761285 | Nuvaila Limited | USTEKINUMAB | 45 mg/.5mL | 1 VIAL in 1 CARTON (84612-855-01) / .5 mL in 1 VIAL |
| 84612-876-01 | 84612-876 | HUMAN PRESCRIPTION DRUG | WEZLANA | ustekinumab-auub | INJECTION, SOLUTION | SUBCUTANEOUS | 20250101 | N/A | BLA | BLA761285 | Nuvaila Limited | USTEKINUMAB | 45 mg/.5mL | 1 SYRINGE in 1 CARTON (84612-876-01) / .5 mL in 1 SYRINGE |
| 84612-889-01 | 84612-889 | HUMAN PRESCRIPTION DRUG | WEZLANA | ustekinumab-auub | INJECTION, SOLUTION | SUBCUTANEOUS | 20250101 | N/A | BLA | BLA761285 | Nuvaila Limited | USTEKINUMAB | 90 mg/mL | 1 SYRINGE in 1 CARTON (84612-889-01) / 1 mL in 1 SYRINGE |
| 84612-089-01 | 84612-089 | HUMAN PRESCRIPTION DRUG | WEZLANA | ustekinumab-auub | INJECTION, SOLUTION | SUBCUTANEOUS | 20250101 | N/A | BLA | BLA761285 | Nuvaila Limited | USTEKINUMAB | 90 mg/mL | 1 SYRINGE in 1 CARTON (84612-089-01) / 1 mL in 1 SYRINGE |
| 84612-076-01 | 84612-076 | HUMAN PRESCRIPTION DRUG | WEZLANA | ustekinumab-auub | INJECTION, SOLUTION | SUBCUTANEOUS | 20250101 | N/A | BLA | BLA761285 | Nuvaila Limited | USTEKINUMAB | 45 mg/.5mL | 1 SYRINGE in 1 CARTON (84612-076-01) / .5 mL in 1 SYRINGE |
| 84612-055-01 | 84612-055 | HUMAN PRESCRIPTION DRUG | WEZLANA | ustekinumab-auub | INJECTION, SOLUTION | SUBCUTANEOUS | 20250101 | N/A | BLA | BLA761285 | Nuvaila Limited | USTEKINUMAB | 45 mg/.5mL | 1 VIAL in 1 CARTON (84612-055-01) / .5 mL in 1 VIAL |